Article

New laboratory will focus on early detection of eye diseases

Jena, Germany-Carl Zeiss Meditec AG and Ilmenau Technical University, Ilmenau, Germany, have opened a new ophthalmology laboratory at the university’s Institute for Biomedical Technology and Computer Science with the goal of improving the diagnosis and treatment of eye diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration, and arterial/venous occlusion.

Jena, Germany-Carl Zeiss Meditec AG and Ilmenau Technical University, Ilmenau, Germany, have opened a new ophthalmology laboratory at the university’s Institute for Biomedical Technology and Computer Science with the goal of improving the diagnosis and treatment of eye diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration, and arterial/venous occlusion. The institute also will educate students learning about biomedical technology.

“This lab represents a high point in the successful collaboration between our company and the university,” said Ulrich Krauss, president and chief executive officer of Carl Zeiss Meditec. “It represents a continuation of our strategy to offer innovative device systems which incorporate the latest scientific and research findings to doctors.”

The German state of Thuringia Ministry of Education and Arts provided support for the laboratory’s research and development infrastructure. In addition to Carl Zeiss Meditec, partners in the laboratory’s research include the other institutes, companies, and universities that are members of the OphthalmoInnovation Thüringen e.V. group. Some of the institute’s projects are sponsored by the Federal Ministry for Education and Research in Germany.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.